Bisphosphonates are osteoporosis drugs taken orally to slow or stop the natural process that dissolves bone tissue, resulting in maintained or increased bone density and strength, and thus either preventing the development of osteoporosis, or slowing the rate of bone thinning and thereby reducing the risk of broken bones.

A new study, however, published in the August 2016 issue of the American Journal of Ophthalmology, suggests that continuous users of oral bisphosphonates may face a higher risk of developing wet AMD. The study’s authors caution that given the observational nature of this study and limitation of the data, future studies are needed to confirm these findings.

Click here ^[1] to access an abstract of the study.